{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:19:47Z","timestamp":1778260787569,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.phrs.2014.03.008","type":"journal-article","created":{"date-parts":[[2014,4,3]],"date-time":"2014-04-03T16:00:45Z","timestamp":1396540845000},"page":"34-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Dapagliflozin: Glucuretic action and beyond"],"prefix":"10.1016","volume":"82","author":[{"given":"Pitchai","family":"Balakumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karupiah","family":"Sundram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sokkalingam A.","family":"Dhanaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2014.03.008_bib0005","unstructured":"IDF DIABETES ATLAS. Sixth Edition. http:\/\/www.idf.org\/diabetesatlas [accessed 29.01.14]."},{"key":"10.1016\/j.phrs.2014.03.008_bib0010","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.cellsig.2013.05.009","article-title":"Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials","volume":"25","author":"Balakumar","year":"2013","journal-title":"Cell Signal"},{"key":"10.1016\/j.phrs.2014.03.008_bib0015","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1111\/j.1476-5381.2012.01938.x","article-title":"PPAR\u03b3 activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders","volume":"166","author":"Balakumar","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.phrs.2014.03.008_bib0020","first-page":"1","article-title":"Alogliptin: new addition to existing gliptins for the management of type-2 diabetes mellitus","volume":"3","author":"Balakumar","year":"2013","journal-title":"RGUHS J Pharm Sci"},{"key":"10.1016\/j.phrs.2014.03.008_bib0025","unstructured":"FDA Press News. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm380829.htm [accessed 15.01.14]."},{"key":"10.1016\/j.phrs.2014.03.008_bib0030","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.phrs.2012.01.004","article-title":"Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?","volume":"65","author":"Balakumar","year":"2012","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.phrs.2014.03.008_bib0035","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1874467211205020219","article-title":"PPAR ligands and cardiovascular disorders: friend or foe","volume":"5","author":"Balakumar","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"10.1016\/j.phrs.2014.03.008_bib0040","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cellsig.2011.09.007","article-title":"Healing the diabetic heart: does myocardial preconditioning work?","volume":"24","author":"Balakumar","year":"2012","journal-title":"Cell Signal"},{"key":"10.1016\/j.phrs.2014.03.008_bib0045","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s12012-012-9182-y","article-title":"Adenosine transport blockade restores attenuated cardioprotective effects of adenosine preconditioning in the isolated diabetic rat heart: potential crosstalk with opioid receptors","volume":"13","author":"Sharma","year":"2013","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.phrs.2014.03.008_bib0050","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ejphar.2012.10.012","article-title":"Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy","volume":"698","author":"Kadian","year":"2013","journal-title":"Eur J Pharmacol"},{"issue":"7398","key":"10.1016\/j.phrs.2014.03.008_bib0055","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/485S14a","article-title":"Public health: India's diabetes time bomb","volume":"485","author":"Shetty","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2014.03.008_bib0060","first-page":"180","article-title":"Prevalence of diabetes in the Malaysian National Health Morbidity Survey III 2006","volume":"65","author":"Letchuman","year":"2010","journal-title":"Med J Malaysia"},{"key":"10.1016\/j.phrs.2014.03.008_bib0065","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/dme.12161","article-title":"Prevalence of diabetes in Malaysia and usefulness of HbA1c as a diagnostic criterion","volume":"30","author":"Wan Nazaimoon","year":"2013","journal-title":"Diabet Med"},{"key":"10.1016\/j.phrs.2014.03.008_bib0070","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1345\/aph.1Q538","article-title":"Dapagliflozin for the treatment of type 2 diabetes","volume":"46","author":"Anderson","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.phrs.2014.03.008_bib0075","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1152\/ajpcell.00450.2011","article-title":"Expression of Na+-d-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences","volume":"302","author":"Sabolic","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.phrs.2014.03.008_bib0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.phrs.2014.03.008_bib0085","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.ajkd.2008.12.031","article-title":"Glucose control by the kidney: an emerging target in diabetes","volume":"53","author":"Marsenic","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.phrs.2014.03.008_bib0090","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3810\/pgm.2012.07.2569","article-title":"Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin","volume":"124","author":"Jabbour","year":"2012","journal-title":"Postgrad Med"},{"key":"10.1016\/j.phrs.2014.03.008_bib0095","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/DMSO.S22503","article-title":"Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus","volume":"5","author":"Whaley","year":"2012","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.phrs.2014.03.008_bib0100","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1463-1326.2010.01216.x","article-title":"Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight","volume":"12","author":"Zhang","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.phrs.2014.03.008_bib0105","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/clpt.2008.251","article-title":"a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.03.008_bib0110","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.phrs.2014.03.008_bib0115","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/bcp.12056","article-title":"The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus","volume":"76","author":"Kasichayanula","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.phrs.2014.03.008_bib0120","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1038\/psp.2013.20","article-title":"A nonlinear mixed effects pharmacokinetic model for dapagliflozin and dapagliflozin 3-O-glucuronide in renal or hepatic impairment","volume":"2","author":"van der Walt","year":"2013","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"10.1016\/j.phrs.2014.03.008_bib0125","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2014.03.008_bib0130","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1463-1326.2011.01359.x","article-title":"Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus","volume":"13","author":"Kasichayanula","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.phrs.2014.03.008_bib0135","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial","volume":"13","author":"Strojek","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.phrs.2014.03.008_bib0140","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(10)60407-2","article-title":"Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Bailey","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2014.03.008_bib0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.phrs.2014.03.008_bib0150","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.phrs.2014.03.008_bib0155","first-page":"S6","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin","volume":"138","author":"Nauck","year":"2013","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.phrs.2014.03.008_bib0160","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2014.03.008_bib0165","doi-asserted-by":"crossref","DOI":"10.1111\/dom.12263","article-title":"Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin","author":"Grandy","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.phrs.2014.03.008_bib0170","doi-asserted-by":"crossref","DOI":"10.1111\/dom.12261","article-title":"Modeling effects of SGLT-2 Inhibitor dapagliflozin treatment vs. standard diabetes therapy on cardiovascular and microvascular outcomes","author":"Dziuba","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.phrs.2014.03.008_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2013.11.002","article-title":"Dapagliflozin as monotherapy in drug-naive asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study","volume":"36","author":"Ji","year":"2014","journal-title":"Clin Ther."},{"key":"10.1016\/j.phrs.2014.03.008_bib0180","article-title":"Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis","author":"Goring","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.phrs.2014.03.008_bib0185","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-Week, multicenter, randomized, double-blind, placebo-controlled study","volume":"37","author":"Jabbour","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2014.03.008_bib0190","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1463-1326.2012.01630.x","article-title":"Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin","volume":"14","author":"Ljunggren","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.phrs.2014.03.008_bib0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jdiacomp.2013.04.012","article-title":"Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.phrs.2014.03.008_bib0200","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","article-title":"Urinary tract infections in patients with diabetes treated with dapagliflozin","volume":"27","author":"Johnsson","year":"2013","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.phrs.2014.03.008_bib0205","doi-asserted-by":"crossref","DOI":"10.1007\/s13300-014-0053-3","article-title":"Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus","author":"Reilly","year":"2014","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.phrs.2014.03.008_bib0210","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2014.03.008_bib0215","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/dia.2013.0167","article-title":"Changes in insulin Sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin","volume":"16","author":"Mudaliar","year":"2014","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.phrs.2014.03.008_bib0220","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","author":"Kohan","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.phrs.2014.03.008_bib0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s13300-010-0006-4","article-title":"Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members","volume":"1","author":"Chen","year":"2010","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.phrs.2014.03.008_bib0230","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.phrs.2014.03.008_bib0235","unstructured":"http:\/\/www.astrazeneca.com\/Media\/Press-releases\/Article\/13012014--us-fda-approves-farxiga-dapagliflozin [accessed 06.03.14]."},{"key":"10.1016\/j.phrs.2014.03.008_bib0240","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661814000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T05:23:40Z","timestamp":1538717020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661814000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":48,"alternative-id":["S1043661814000371"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2014.03.008","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin: Glucuretic action and beyond","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2014.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}